Advertisement
Research ArticleArticle

Trimethoprim and Sulfamethoxazole are Selective Inhibitors of CYP2C8 and CYP2C9, Respectively

Xia Wen, Jun-Sheng Wang, Janne T. Backman, Jouko Laitila and Pertti J. Neuvonen
Drug Metabolism and Disposition June 2002, 30 (6) 631-635; DOI: https://doi.org/10.1124/dmd.30.6.631
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Trimethoprim and Sulfamethoxazole are Selective Inhibitors of CYP2C8 and CYP2C9, Respectively

Xia Wen, Jun-Sheng Wang, Janne T. Backman, Jouko Laitila and Pertti J. Neuvonen
Drug Metabolism and Disposition June 1, 2002, 30 (6) 631-635; DOI: https://doi.org/10.1124/dmd.30.6.631
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement